Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863035 | 1.00 | CYP1A2 (0.56) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| Bromide SCHEMBL741360 | 0.98 | CYP1A2 (0.55) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL1855324 | 0.98 | CYP1A2 (0.53) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL7418522 | 0.95 | CYP1A2 (0.50) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL10084759 | 0.95 | CYP1A2 (0.50) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL24001256 | 0.93 | ALDH1A1 (0.50) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL7418518 | 0.93 | ALDH1A1 (0.50) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL24001095 | 0.93 | ALDH1A1 (0.50) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL24757426 | 0.93 | CYP1A2 (0.48) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL27065452 | 0.91 | ALDH1A1 (0.48) | CYP1A2MAPK1SMN1; SMN2HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103534236-B | Method for producing granules | 住友化学株式会社 | 2016-08-17 | — | — | CN | disclosed |
| EP-1951663-B1 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-20 | — | — | EP | disclosed |
| CN-103974929-A | Method for producing hydrohalic acid salt of halogenated alkyl amine | SUMITOMO CHEMICAL CO | 2014-08-06 | — | — | CN | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| CN-103534236-A | Method for producing granules | SUMITOMO CHEMICAL CO | 2014-01-22 | — | — | CN | disclosed |
| CN-103459384-A | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS INC | 2013-12-18 | — | — | CN | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2007060215-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2007-05-31 | — | — | WO | disclosed |
| EP-1751124-A2 | RAF MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112932-A2 | RAF MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | disclosed |
| US-5580885-A | FOR TREATMENT OF GASTROINTESTINAL, CARDIOVASCULAR OR NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0609278-A1 | IMIDAZOPYRIDINES AND INDOLIZINES AS 5-HT 4 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-08-10 | — | — | EP | disclosed |
| EP-0604494-A1 | 5-HT 4? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993008187-A1 | IMIDAZOPYRIDINES AND INDOLIZINES AS 5-HT4 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-04-29 | — | — | WO | disclosed |
| WO-1993005038-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-03-18 | — | — | WO | disclosed |
| US-5102890-A | Anxiolytic agents | RHONE-POULENC SANTE (FR) | 1992-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | CYP1A2 878/4885MAPK1 134/4885SMN1; SMN2 3818/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | CYP1A2 1244/4885MAPK1 105/4885SMN1; SMN2 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.